It was a pleasure to speak with Dr Lynsey Drewett (University of Cambridge, Cambridge, UK) around the PARTNER study, investigating the efficacy and safety of the addition of olaparib to neoadjuvant platinum-based chemotherapy in the treatment of basal TNBC and/or gBRCA breast cancer.
The abstract ‘PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.’ (Abstract number CT562) was presented at AACR 2022, 8-13 April, 2022
Questions
- What are the unmet needs in the treatment of triple negative breast cancer (TNBC) and germline BRCA (gBRCA) breast cancer? (0:18)
- What was the rationale for the addition of olaparib to neoadjuvant platinum-based chemotherapy in the treatment of basal TNBC and/or gBRCA breast cancer? (1:26)
- What are the aims, design and eligibility criteria for the PARTNER study? (2:49)
- What are the endpoints for stage 1, 2 and 3 of the study and how well have these been achieved so far? (3:54)
- Please could you give a brief overview of the Partnering substudy? (4:55)
Disclosures: Lynsey Drewett has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the AACR annual meeting 2022.
